Cargando…
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283714/ https://www.ncbi.nlm.nih.gov/pubmed/35846311 http://dx.doi.org/10.3389/fendo.2022.935759 |
_version_ | 1784747386530168832 |
---|---|
author | Mondin, Alessandro Manara, Renzo Voltan, Giacomo Tizianel, Irene Denaro, Luca Ferrari, Marco Barbot, Mattia Scaroni, Carla Ceccato, Filippo |
author_facet | Mondin, Alessandro Manara, Renzo Voltan, Giacomo Tizianel, Irene Denaro, Luca Ferrari, Marco Barbot, Mattia Scaroni, Carla Ceccato, Filippo |
author_sort | Mondin, Alessandro |
collection | PubMed |
description | INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only in somatotroph adenomas. This systematic review and meta-analysis aim to summarize the effect of PAS on the shrinkage of the pituitary adenomas in patients with acromegaly or CD. MATERIALS AND METHODS: We searched the Medline database for original studies in patients with acromegaly or CD receiving PAS as monotherapy, that assessed the proportion of significant tumor shrinkage in their series. After data extraction and analysis, a random-effect model was used to estimate pooled effects. Quality assessment was performed with a modified Joanna Briggs’s Institute tool and the risk of publication bias was addressed through Egger’s regression and the three-parameter selection model. RESULTS: The electronic search identified 179 and 122 articles respectively for acromegaly and CD. After study selection, six studies considering patients with acromegaly and three with CD fulfilled the eligibility criteria. Overall, 37.7% (95%CI: [18.7%; 61.5%]) of acromegalic patients and 41.2% (95%CI: [22.9%; 62.3%]) of CD patients achieved significant tumor shrinkage. We identified high heterogeneity, especially in acromegaly (I(2) of 90% for acromegaly and 47% for CD), according to the low number of studies included. DISCUSSION: PAS treatment is effective in reducing tumor size, especially in acromegalic patients. This result strengthens the role of PAS treatment in pituitary adenomas, particularly in those with an invasive behavior, with progressive growth and/or extrasellar extension, with a low likelihood of surgical gross-total removal, or with large postoperative residual tissue. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022328152, identifier CRD42022328152 |
format | Online Article Text |
id | pubmed-9283714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92837142022-07-16 Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis Mondin, Alessandro Manara, Renzo Voltan, Giacomo Tizianel, Irene Denaro, Luca Ferrari, Marco Barbot, Mattia Scaroni, Carla Ceccato, Filippo Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only in somatotroph adenomas. This systematic review and meta-analysis aim to summarize the effect of PAS on the shrinkage of the pituitary adenomas in patients with acromegaly or CD. MATERIALS AND METHODS: We searched the Medline database for original studies in patients with acromegaly or CD receiving PAS as monotherapy, that assessed the proportion of significant tumor shrinkage in their series. After data extraction and analysis, a random-effect model was used to estimate pooled effects. Quality assessment was performed with a modified Joanna Briggs’s Institute tool and the risk of publication bias was addressed through Egger’s regression and the three-parameter selection model. RESULTS: The electronic search identified 179 and 122 articles respectively for acromegaly and CD. After study selection, six studies considering patients with acromegaly and three with CD fulfilled the eligibility criteria. Overall, 37.7% (95%CI: [18.7%; 61.5%]) of acromegalic patients and 41.2% (95%CI: [22.9%; 62.3%]) of CD patients achieved significant tumor shrinkage. We identified high heterogeneity, especially in acromegaly (I(2) of 90% for acromegaly and 47% for CD), according to the low number of studies included. DISCUSSION: PAS treatment is effective in reducing tumor size, especially in acromegalic patients. This result strengthens the role of PAS treatment in pituitary adenomas, particularly in those with an invasive behavior, with progressive growth and/or extrasellar extension, with a low likelihood of surgical gross-total removal, or with large postoperative residual tissue. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022328152, identifier CRD42022328152 Frontiers Media S.A. 2022-07-01 /pmc/articles/PMC9283714/ /pubmed/35846311 http://dx.doi.org/10.3389/fendo.2022.935759 Text en Copyright © 2022 Mondin, Manara, Voltan, Tizianel, Denaro, Ferrari, Barbot, Scaroni and Ceccato https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Mondin, Alessandro Manara, Renzo Voltan, Giacomo Tizianel, Irene Denaro, Luca Ferrari, Marco Barbot, Mattia Scaroni, Carla Ceccato, Filippo Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis |
title | Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis |
title_full | Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis |
title_fullStr | Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis |
title_short | Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis |
title_sort | pasireotide-induced shrinkage in gh and acth secreting pituitary adenoma: a systematic review and meta-analysis |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283714/ https://www.ncbi.nlm.nih.gov/pubmed/35846311 http://dx.doi.org/10.3389/fendo.2022.935759 |
work_keys_str_mv | AT mondinalessandro pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT manararenzo pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT voltangiacomo pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT tizianelirene pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT denaroluca pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT ferrarimarco pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT barbotmattia pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT scaronicarla pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis AT ceccatofilippo pasireotideinducedshrinkageinghandacthsecretingpituitaryadenomaasystematicreviewandmetaanalysis |